[REVISION HISTORY]

Bundibugyo Ebola outbreak and vaccine response

4 recorded revisions of this situation.

What changed

2026-11-04 21:04 UTC → 2026-11-04 23:04 UTC · added ~~removed~~

Following an outbreak of the Bundibugyo (BDBV) Ebola virus strain in the Democratic Republic of the Congo, with cases also reported in Uganda, Kenya, and Nigeria, the European Medicines Agency (EMA) and the African Medicines Agency (AMA) issued a joint position paper calling for the rapid commencement of clinical trials. The agencies recommended that national regulatory authorities in African countries provide timely approvals and discussed scientific justifications for potentially bypassing certain animal toxicity studies for vaccines using established platforms like mRNA. In response to the emergency, a vaccine development project was initiated with support from the U.S. Biomedical Advanced Research and Development Authority (BARDA). A partnership including SK bioscience, IAVI, Hilleman Laboratories, and IDT Biologika received funding of up to $99 million to develop, manufacture, and clinically evaluate a single-dose vaccine candidate using the recombinant vesicular stomatitis virus (rVSV) platform. SK bioscience is tasked with vaccine scale-up and mass production, while its German subsidiary, IDT Biologika, handles fill-and-finish processes. As of November 4, 2026, the Africa Centres for Disease Control and Prevention reports the outbreak has resulted in over 10,444 confirmed cases and 5,300 deaths, maintaining a fatality rate of more than 50 percent. The World Health Organization (WHO) has approved clinical trials for two new vaccine candidates specifically developed for the Bundibugyo strain: ChAdOx1 BDBV, developed by the University of Oxford and the Serum Institute of India, and Moderna’s mRNA-1469. These trials are being led by the DRC’s National Institute for Biomedical ~~Research.~~ Research, with researchers expecting initial results by early 2027. While the Ervebo vaccine is in use, WHO chief Tedros Adhanom Ghebreyesus noted it is approved for Ebola but not specifically for the Bundibugyo variant, and emphasized that vaccines should not replace immediate measures such as contact tracing, isolation, and safe burial practices.

Versions

Select a version to see what changed compared to the one before it.